TY - JOUR
T1 - MicroRNA-155 expression is enhanced by T-cell receptor stimulation strength and correlates with improved tumor control in Melanoma
AU - Martinez-Usatorre, Amaia
AU - Sempere, Lorenzo F.
AU - Carmona, Santiago J.
AU - Carretero-Iglesia, Laura
AU - Monnot, Gwennaëlle
AU - Speiser, Daniel E.
AU - Rufer, Nathalie
AU - Donda, Alena
AU - Zehn, Dietmar
AU - Jandus, Camilla
AU - Romero, Pedro
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/6
Y1 - 2019/6
N2 - microRNAs are short noncoding RNAs that regulate protein expression posttranscriptionally.We previously showed that miR-155 promotes effector CD8+ T-cell responses. However, little is known about the regulation of miR-155 expression. Here, we report that antigen affinity and dose determine miR-155 expression in CD8+ T cells. In B16 tumors expressing a low-affinity antigen ligand, tumorspecific infiltrating CD8+ T cells showed variable miR-155 expression, whereby high miR-155 expression was associated with more cytokine-producing cells and tumor control. Moreover, anti-PD-1 treatment led to both increased miR-155 expression and tumor control by specific CD8+ T cells. In addition, miR-155 overexpression enhanced exhausted CD8+ T-cell persistence in the LCMV cl13 chronic viral infection model. In agreement with these observations in mouse models, miR-155 expression in human effector memory CD8+ T cells positively correlated with their frequencies in tumor-infiltrated lymph nodes of melanoma patients. Low miR-155 target gene signature in tumors was associated with prolonged overall survival in melanoma patients. Altogether, these results raise the possibility that high miR-155 expression in CD8+ tumorinfiltrating T cells may be a surrogate marker of the relative potency of in situ antigen-specific CD8+ T-cell responses.
AB - microRNAs are short noncoding RNAs that regulate protein expression posttranscriptionally.We previously showed that miR-155 promotes effector CD8+ T-cell responses. However, little is known about the regulation of miR-155 expression. Here, we report that antigen affinity and dose determine miR-155 expression in CD8+ T cells. In B16 tumors expressing a low-affinity antigen ligand, tumorspecific infiltrating CD8+ T cells showed variable miR-155 expression, whereby high miR-155 expression was associated with more cytokine-producing cells and tumor control. Moreover, anti-PD-1 treatment led to both increased miR-155 expression and tumor control by specific CD8+ T cells. In addition, miR-155 overexpression enhanced exhausted CD8+ T-cell persistence in the LCMV cl13 chronic viral infection model. In agreement with these observations in mouse models, miR-155 expression in human effector memory CD8+ T cells positively correlated with their frequencies in tumor-infiltrated lymph nodes of melanoma patients. Low miR-155 target gene signature in tumors was associated with prolonged overall survival in melanoma patients. Altogether, these results raise the possibility that high miR-155 expression in CD8+ tumorinfiltrating T cells may be a surrogate marker of the relative potency of in situ antigen-specific CD8+ T-cell responses.
UR - http://www.scopus.com/inward/record.url?scp=85067218169&partnerID=8YFLogxK
U2 - 10.1158/2326-6066.CIR-18-0504
DO - 10.1158/2326-6066.CIR-18-0504
M3 - Article
C2 - 31043416
AN - SCOPUS:85067218169
SN - 2326-6066
VL - 7
SP - 1013
EP - 1024
JO - Cancer Immunology Research
JF - Cancer Immunology Research
IS - 6
ER -